Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.

ABSTRACT:

Objective

The clinical efficacy and safety profile of trastuzumab deruxtecan (T-DXd) have been demonstrated in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer (BC). It is, however, necessary to evaluate the value of T-DXd considering both its clinical efficacy and its cost, given that it is high. This study aimed to evaluate the cost-effectiveness of T-DXd versus chemotherapy in patients with previously treated HER2-low advanced BC.

Methods

We used a partitioned survival model that included three mutually exclusive health states. The patients in the model were identified based on their clinical characteristics and outcomes from the DESTINY-Breast04. Probabilistic and one-way sensitivity analyses were performed to ev

SUBMITTER: Shi D 

PROVIDER: S-EPMC10449172 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature